Study Detail: Allergan RVO VO1
Trial Description Summary
A 12 month Phase 2, Masked-Randomized Single Dose Study of the Safety and Efficacy of AGN-208397 (Beclomethasone Dipropionate) in Patients with ME associated with RVO.
Basic Trial Information
Phase: II
Disease Status: Retinal Vein Occlusion
Age: 18 or older
Sponsor: Allergan
Protocol #: 208397-001
Status: Enrolling
Study Duration: 1 year
Eligibility Criteria:
OPHTHALMIC INCLUSION-
• Non-ischemic BRVO or CRVO with ME involving the center of the macula (fovea) with vision decrease attributable to the ME
• CRVO- duration of < 9 months or BRVO- duration of < 12 months
• Central Sub-field Cirrus OCT = 300 µm (Stratus OCT = 275 µm)
• BCVA approx. 20/320-20/40
OPHTHALMIC EXCLUSION-
• IOP >21 or glaucoma in either eye at screening or baseline, or in the past
• Hx of Laser Photocoagulation to the SE within 3 months of Baseline
• Hx of Intravitreal Injectable Drug other than corticosteroids in the SE within 2 months of Baseline
• Hx of Intravitreal or Periocular Corticosteroids within 4 months of Baseline
• Hx of systemic (oral, Intavenous, IM, epidural, rectal, inhaled, or extensive dermal) corticosteroids within 3 months of Baseline
• FE approx. 20/200 or worse
• Current or hx of ocular disease in the SE that may confound assessment or affect central vision (for example: CNV-AMD, GA, DR, Uveitis, Angioid Streaks, CSR, Histo, Pathologic Myopia, RD, ERM, Mac Hole or Significant Cataract.
• Any active ocular inflammation or infection at screening or hx of toxo or cytomegalovirus or herpes infection in either eye
• Aphakia or violation of the PC unless it occurred as result of YAG in associated with prior PCIOL.
• Hx of PK or Vitrectomy
• Cataract or LASIK surgery within the last 3 months
• Plans for cataract extraction in the next year
GENERAL MEDICAL EXCLUSION-
• Uncontrolled systemic disease
Other inclusion/exclusion criteria as outlined in the protocol will be screened by the study coordinator
Study Title
A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
Trial Contact Information
Site: Beachwood
Study Coordinator: Kim DuBois
216/831-5704 ext. 253


